Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | APAF1 | O14727 | 2/20 | 0.42 |
| ▸ | TDP2 | O95551 | 2/20 | 0.42 |
| ▸ | NSD2 | O96028 | 2/20 | 0.42 |
| ▸ | HKDC1 | Q2TB90 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | GALK1 | P51570 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.39 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8958544 | 0.88 | DNMT1 (0.52) | DNMT1MAPTHTTKMT2ALMNA | |
| SCHEMBL8843222 | 0.78 | NSD2 (0.48) | DNMT1MAPTKMT2ANSD2MEN1 | |
| SCHEMBL1420707 | 0.78 | DNMT1 (0.41) | DNMT1MAPTHTTKMT2ALMNA | |
| SCHEMBL8958416 | 0.76 | MAPT (0.46) | DNMT1MAPTHTTKMT2ALMNA | |
| Triaziquone SCHEMBL8303 | 0.76 | DNMT1 (0.48) | DNMT1MAPTHTTKMT2ALMNA | |
| Triaziquone SCHEMBL6000230 | 0.75 | DNMT1 (0.47) | DNMT1MAPTHTTKMT2ALMNA | |
| Triaziquone SCHEMBL5054475 | 0.75 | DNMT1 (0.47) | DNMT1MAPTHTTKMT2ALMNA | |
| Triaziquone SCHEMBL8482641 | 0.75 | DNMT1 (0.47) | DNMT1MAPTHTTKMT2ALMNA | |
| Triaziquone SCHEMBL8993238 | 0.75 | DNMT1 (0.47) | DNMT1MAPTHTTKMT2ALMNA | |
| Triaziquone SCHEMBL7738777 | 0.75 | DNMT1 (0.47) | DNMT1MAPTHTTKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12297500-B2 | Transcriptomic index for characterizing the cellular repair response after soft tissue injury in diarthrodial joints | RUSH UNIVERSITY MEDICAL CENTER (US) | 2025-05-13 | — | — | US | claimed |
| CN-114333292-B | Traffic restoration method based on trajectory reconstruction technology | 上海电科智能系统股份有限公司 | 2022-11-18 | — | — | CN | claimed |
| EP-2900236-B1 | TREATMENT OF WOLFRAM SYNDROME-RELATED NEURODEGENERATION | UNIV BIRMINGHAM (GB) | 2019-01-16 | — | — | EP | claimed |
| US-20090123447-A1 | COMPOSITIONS AND METHODS TO INHIBIT RNA VIRAL REPRODUCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2009-05-14 | — | — | US | claimed |
| EP-1017852-A1 | OBTAINING NUCLEIC ACID SEQUENCES | The Victoria University of Manchester (GB) | 2000-07-12 | — | — | EP | claimed |
| US-6066457-A | ANCHORING SINGLE STRANDED CDNA PRODUCED FROM STARTING MATERIAL AND USING RANDOM PRIMING AND SEPARATION STEPS TO PRODUCE SHORTER RANDOM SIZE DNA FOR UNIFORM POLYMERASE CHAIN REACTION AMPLIFICATION USEFUL IN SUBTRACTIVE HYBRIDIZATION | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2000-05-23 | — | — | US | claimed |
| WO-1999018236-A1 | OBTAINING NUCLEIC ACID SEQUENCES | THE VICTORIA UNIVERSITY OF MANCHESTER (GB) | 1999-04-15 | — | — | WO | claimed |
| EP-0864001-A1 | GLOBAL AMPLIFICATION OF NUCLEIC ACIDS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1998-09-16 | — | — | EP | claimed |
| WO-1998008973-A1 | GLOBAL AMPLIFICATION OF NUCLEIC ACIDS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1998-03-05 | — | — | WO | claimed |
| US-5591575-A | Subtraction hybridization employing aziridinylbenoquinone cross-linking agents | AMERSHAM INTERNATIONAL PLC (GB) | 1997-01-07 | — | — | US | claimed |
| US-5589339-A | Subtraction hybridization | AMERSHAM INTERNATIONAL PLC (GB) | 1996-12-31 | — | — | US | claimed |
| US-4238484-A | O,O-DIALKYL-O-/3-BENZOTHIENGLYOXYLONITRILE OXIMO/PHOSPHATE | ABBOTT LABORATORIES (US) | 1980-12-09 | — | — | US | claimed |
| WO-2026107259-A1 | BIOMARKERS FOR CANCER DETECTION | NEXOSOME ONCOLOGY LLC (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4219735-B1 | METHOD AND APPARATUS FOR ANALYTE DETECTION USING AN ELECTROCHEMICAL BIOSENSOR | ABBOTT DIABETES CARE (US) | 2026-04-01 | — | — | EP | disclosed |
| EP-3496763-B1 | PYRROLOBENZODIAZEPINE PRODRUGS AND ANTIBODY CONJUGATES THEREOF | GENENTECH INC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20260083672-A1 | FORMULATIONS AND DOSAGE AMOUNTS FOR ADMINISTERING AN ANTI-DPP3 ANTIBODY OR FRAGMENT THEREOF TO HUMANS | 4TEEN4 Pharmaceuticals GmbH (DE) | 2026-03-26 | — | — | US | disclosed |
| US-4704384-A | BRAIN TUMORS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1987-11-03 | — | — | US | disclosed |
| US-4238484-A | O,O-DIALKYL-O-/3-BENZOTHIENGLYOXYLONITRILE OXIMO/PHOSPHATE | ABBOTT LABORATORIES (US) | 1980-12-09 | — | — | US | disclosed |
| US-4233215-A | Aziridinyl quinone antitumor agents | UNITED STATES OF AMERICA (US) | 1980-11-11 | — | — | US | disclosed |
| US-4146622-A | AZIRIDINYL QUINONE ANTI-TRANSPLANTED TUMOR AGENTS | THE GOVERNMENT OF THE UNITED STATES (US) | 1979-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083672-A1 | FORMULATIONS AND DOSAGE AMOUNTS FOR ADMINISTERING AN ANTI-DPP3 ANTIBODY OR FRAGMENT THEREOF TO HUMANS | DPP3, DPP4, TREH | DNMT1 3993/4885MAPT 824/4885HTT 3417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.